Maria De Santis
A5075511405- Bladder and Urothelial Cancer Treatments
- Systemic Sclerosis and Related Diseases
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Inflammatory Myopathies and Dermatomyositis
- Rheumatoid Arthritis Research and Therapies
- Testicular diseases and treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Renal cell carcinoma treatment
- Systemic Lupus Erythematosus Research
- COVID-19 Clinical Research Studies
- Prostate Cancer Treatment and Research
- Multiple and Secondary Primary Cancers
- SARS-CoV-2 and COVID-19 Research
- Cancer Diagnosis and Treatment
- Liver Diseases and Immunity
- Long-Term Effects of COVID-19
- Prostate Cancer Diagnosis and Treatment
- Inflammasome and immune disorders
- Cancer Genomics and Diagnostics
- Dermatologic Treatments and Research
- Monoclonal and Polyclonal Antibodies Research
- Urological Disorders and Treatments
- Eosinophilic Disorders and Syndromes
- Urologic and reproductive health conditions
Humanitas University
2014-2025
IRCCS Humanitas Research Hospital
2015-2025
Medical University of Vienna
2017-2025
Charité - Universitätsmedizin Berlin
2018-2025
Humboldt-Universität zu Berlin
2025
Freie Universität Berlin
2025
Istituti di Ricovero e Cura a Carattere Scientifico
2010-2024
Comprehensive Cancer Center Vienna
2024
Instituto Maimónides de Investigación Biomédica de Córdoba
2024
Hospital Universitario Reina Sofía
2024
There is considerable variation in disease behavior among patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes 2019 (Covid-19). Genomewide association analysis may allow for identification of potential genetic factors involved development Covid-19.
Purpose This is the first randomized phase II/III trial comparing two carboplatin-based chemotherapy regimens in patients with urothelial cancer who are ineligible (“unfit”) for cisplatin chemotherapy. Patients and Methods The primary objective of III part this study was to compare overall survival (OS) chemotherapy-naive measurable disease an impaired renal function (glomerular filtration rate < 60 but > 30 mL/min) and/or performance score 2 were randomly assigned receive either...
Objectives To determine the causes of death and risk factors in systemic sclerosis (SSc). Methods Between 2000 2011, we examined certificates all French patients with SSc to death. Then developed a score associated all-cause mortality from international European Scleroderma Trials Research (EUSTAR) database. Candidate prognostic were tested by Cox proportional hazards regression model single variable analysis, followed multiple stratified centres. The bootstrapping technique was used for...
The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that three-drug included paclitaxel had greater antitumor activity and might improve survival.We conducted randomized III to compare paclitaxel/cisplatin/gemcitabine (PCG) GC carcinoma. Primary outcome was overall survival (OS). Secondary outcomes were progression-free (PFS), response rate, toxicity.From 2001 2004, 626...
Interferons interfere with lung repair (IFNs) are central to antiviral immunity. Viral recognition elicits IFN production, which in turn triggers the transcription of IFN-stimulated genes (ISGs), engage various functions. Type I IFNs (IFN-α and IFN-β) widely expressed can result immunopathology during viral infections. By contrast, type III (IFN-λ) responses primarily restricted mucosal surfaces thought confer protection without driving damaging proinflammatory responses. Accordingly, IFN-λ...
In November 2011, the Third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer (GCC) was held in Berlin, Germany. This third conference followed similar meetings 2003 (Essen, Germany) 2006 (Amsterdam, The Netherlands) [Schmoll H-J, Souchon R, Krege S et al. consensus diagnosis treatment germ-cell cancer: a report Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399; S, Beyer J, R second meeting group (EGCCCG): part I. Eur Urol 2008; 53: 478-496; II. 497-513]. A panel 56 60...
Background. Immunomagnetic EpCAM based methods are used to enrich circulating tumor cells (CTCs) in metastatic breast cancer (mBC) patients. negative CTCs may be missed. We addressed the question of reliability an dependent assay CTCs. Methods. To elucidate this issue, our study has been designed assess two different CTC enrichment technologies (i) positive (+) and cell lines (ii) mBC patients dependency on their respective expression. These encompass one anti-EpCAM immunomagnetic...